Heplisav-B: payments to doctors
Payments that named Heplisav-B as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.4M
- Providers
- 11,821
- Transactions
- 21,471
- Average per transaction
- $112
The per-transaction average — $112 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,821 providers the average total is $203, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Dynavax Technologies Corporation | $2,403,441 | 100.0% |